Core Viewpoint - Co-Diagnostics, Inc. has conducted an in silico analysis of its Logix Smart ABC test, confirming its effectiveness against the influenza A H3N2 subclade K, which is significant due to the current flu season and vaccine mismatch [1][2][3]. Group 1: Company Developments - The Logix Smart ABC test has shown high homology against 3,900 influenza sequences, indicating comparable reactivity against the H3N2 subclade K [1]. - The test received CE-marking in November 2020 for the simultaneous detection of influenza A, influenza B, and SARS-CoV-2, with no concerns regarding sensitivity from emerging H3N2 strains [3]. - In November 2025, the company initiated clinical performance testing for a new PCR Flu A/B, COVID-19, RSV point-of-care multiplex test, aimed at FDA 510(k) clearance [4]. Group 2: Industry Context - The World Health Organization reports that seasonal influenza leads to approximately 3–5 million severe illness cases and 290,000–650,000 respiratory fatalities annually [2]. - The current flu vaccine is mismatched with the H3N2 subclade K, which has limited natural immunity in communities, raising concerns about higher hospitalization and death rates [2]. - Preliminary data indicates that countries like Japan and the UK are experiencing earlier flu seasons in 2025, following a record flu season in Australia [2].

Core Insights - VolitionRx Limited has made significant progress in 2025, focusing on the commercialization of its Nu.Q® platform for human diagnostics, with key milestones achieved in cancer and sepsis detection [2][3][4] Group 1: Business Developments - The company received its first order for Nu.Q® Cancer assays for clinical certification in lung cancer and included the Nu.Q® NETs assay in a government-backed program in France for early sepsis detection, valued at approximately $7.3 million [3][4] - Volition signed two licensing agreements with major companies, Werfen and Hologic, marking a strategic move into the human diagnostics market [5] - The company is in discussions with around 10 leading diagnostic and liquid biopsy companies to secure additional licensing agreements, anticipating announcements throughout 2026 [6][7] Group 2: Financial Opportunities - The Total Addressable Markets (TAMs) for Volition's technologies are substantial, including $2.3 billion for lung cancer screening, $23 billion for multi-cancer early detection, and $2.8 billion for sepsis early detection [11] - The company aims to replicate its successful licensing strategy in the veterinary market within the human diagnostics space, with potential for diverse deal structures and recurring revenue [7][10] Group 3: Scientific and Clinical Progress - Volition's Nu.Q® NETs assay is being evaluated in over 20 hospitals across 10 countries for various clinical use cases, indicating its potential to become a routine blood test [8] - The company has achieved significant scientific advancements, including the development of a lateral flow test for quantifying nucleosomes, which aids in clinical decision-making [10] - A large-scale study demonstrated that the Nu.Q® NETs H3.1 biomarker is an independent predictor of mortality in sepsis patients, showcasing the assay's clinical relevance [10]

Core Insights - Castle Biosciences, Inc. announced new data from the largest prospective, multicenter study comparing next-generation sequencing (NGS)-based gene mutation analysis with the combination of DecisionDx-UM and PRAME gene expression for predicting outcomes in uveal melanoma (UM) patients [1][2] Study Findings - The study validated that the combination of DecisionDx-UM and PRAME provides more precise metastatic risk prediction for UM patients than either test used independently [2] - The combination of DecisionDx-UM and PRAME delivers superior predictions of metastasis-free survival (MFS) and overall survival (OS) compared to NGS-based mutation analysis [2] - The study analyzed 1,140 primary UM tumors, including 131 small, early-stage tumors, using NGS to assess seven clusters of recurrent genetic mutations [2] Test Offerings - Castle currently offers three tests for UM: DecisionDx-UM, DecisionDx-PRAME, and DecisionDx-UMSeq, all from a single biopsy sample [3] - These tests provide comprehensive molecular insights for precise risk assessment and informed treatment planning for UM patients [3] Collaborative Ocular Oncology Group (COOG) - COOG is the largest collaborative working group in North America focused on intraocular cancers, particularly uveal melanoma, comprising over 25 leading academic and private ocular oncology centers [4] - COOG has conducted two large multicenter prospective studies of prognostic biomarkers in uveal melanoma, the first of their kind in this cancer [4] DecisionDx-UM Overview - DecisionDx-UM is a gene expression profile test that predicts personalized risk of metastasis from uveal melanoma by stratifying patients into low-, intermediate-, or high-risk groups [5] - The test has been widely adopted as the standard of care in the U.S. and is included in the AJCC Staging Manual and NCCN Guidelines, with nearly 80% of newly diagnosed patients undergoing testing [6]

Core Insights - Cofactor Genomics has received strategic investments from Labcorp and Ascension Ventures to enhance its operations and expand its market presence [1] Company Summary - Cofactor Genomics is a commercial-stage diagnostics company focused on transforming precision oncology through RNA-based predictive tests [1] - The new financing aims to accelerate Cofactor's nationwide expansion and increase patient access to its immunotherapy-response diagnostics [1] Industry Context - Ascension Ventures is the strategic investment arm of 13 leading U.S. health systems across 22 states, representing over $100 billion in assets [1]

Core Insights - Trinity Biotech is advancing its mission to deliver next-generation diabetes management solutions and expand its global market penetration, particularly in the $2 billion+ HbA1c market [1][2] Company Developments - Trinity Biotech has secured regulatory clearances in multiple countries for its next-generation high-capacity HbA1c column system for the Premier Hb9210 analyzer, which is now available in over 10 countries, including the United States [1] - The upgraded column system enhances testing throughput by up to four times compared to the existing system, reduces instrument downtime, and minimizes maintenance requirements, leading to improved operational efficiency [3][7] - The Premier Hb9210 solution is recognized as a gold standard in HbA1c testing, with strong clinical performance confirmed by peer-reviewed studies [3] Market Potential - The global laboratory HbA1c market is currently valued at over $2 billion and is projected to exceed $3.5 billion by 2030, driven by the increasing prevalence of diabetes [2] - The launch of the advanced system in key markets positions Trinity Biotech to capture further growth opportunities in the global diabetes care segment [3] Operational Efficiency - The new column system's operational gains create a more efficient workflow for clinical laboratories, supporting broader adoption of the platform [3] - The latest software update enhances automation of routine tasks, enabling greater productivity and cost savings [7]

As filed with the U.S. Securities and Exchange Commission on December 12, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 20/20 BIOLABS, INC. (Exact name of registrant as specified in its charter) Delaware 8734 57-2272107 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 15810 Gaither ...

Core Viewpoint - Abbott has announced a 6.8% increase in its quarterly common dividend to 63 cents per share, marking its 54th consecutive year of dividend growth and the 408th consecutive quarterly dividend payment since 1924 [1][4]. Group 1: Dividend Information - The quarterly dividend payout has increased more than 70% since 2020 [1][4]. - The cash dividend is payable on February 13, 2026, to shareholders of record as of January 15, 2026 [1]. Group 2: Company Background - Abbott is a global healthcare leader with a diverse portfolio in diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries [3]. - Abbott is a member of the S&P 500 Dividend Aristocrats Index, which includes companies that have increased dividends annually for at least 25 consecutive years [2].

Core Insights - Hologic (HOLX) is positioned to capture market share in the diagnostics sector, despite recent macroeconomic challenges affecting its performance [1] - The U.S. diagnostics market is projected to grow at a CAGR of 9.12% from 2025 to 2030, indicating strong future potential for Hologic [1] Diagnostics Segment Performance - In Q4 of fiscal 2025, Diagnostics revenues increased by 1.5% in constant currency, driven by higher core U.S. molecular diagnostics sales [2] - Organic diagnostics sales, excluding COVID-19 revenues, grew by 4.4% in constant currency [2] - The Molecular Diagnostics unit is the main growth driver, with significant contributions from BV, CV/TV, and Panther Fusion assays [2] Product Developments and Innovations - The Panther Fusion system is highlighted for its efficiency and ability to consolidate testing, utilizing PCR technology for over 23 assays [3] - Recent approvals for the Genius Digital Diagnostics System and Panther Fusion assays are expected to enhance Hologic's market position [4] Competitive Landscape - Abbott (ABT) has expanded its continuous glucose monitor to Android devices, increasing accessibility for users [5] - Roche Holdings (RHHBY) has received CE Mark approval for its mass spectrometry reagent pack and cobas BV/CV assay, broadening its IVD offerings [6] Stock Performance and Valuation - Hologic shares have increased by 3.8% year-to-date, outperforming the industry growth of 3.1% [7] - The company is trading at a forward five-year price-to-sales (P/S) ratio of 3.86X, which is lower than the industry average of 4.35X [9]

Core Insights - Castle Biosciences, Inc. announced a systematic review and meta-analysis demonstrating that the TissueCypher® Barrett's Esophagus test provides clinically validated risk stratification for patients with Barrett's esophagus, outperforming traditional pathology or clinical factors in identifying patients at increased risk of developing esophageal cancer [1][2]. Group 1: Study Findings - The systematic review and meta-analysis consolidated data from six studies, confirming that TissueCypher consistently identifies patients at greater risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) [2]. - The study represents the most comprehensive validation of the TissueCypher test to date, reinforcing its value as an evidence-based tool for risk stratification in Barrett's esophagus [3][5]. - TissueCypher has been shown to be the strongest independent predictor of progression compared to traditional histopathological risk assessment, with high-risk results indicating patients are 6.7 times more likely to progress to HGD or EAC within five years than those with low-risk results [7][9]. Group 2: Clinical Implications - The findings support personalized, risk-aligned patient management aimed at preventing cancer, allowing physicians to identify which patients may benefit from earlier intervention and those who can continue routine surveillance [3][5]. - Patients with high or intermediate-risk results had an annual progression rate of 2.8%, while those with high-risk results had a rate of 5.6% per year, both exceeding the typical 1.7% annual progression rate for patients with low-grade dysplasia [9]. Group 3: Test Overview - TissueCypher is a precision medicine test designed to predict a patient's personalized risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma, indicated for patients with non-dysplastic BE, indefinite for dysplasia, or low-grade dysplasia [6]. - The test utilizes an AI-driven spatialomics approach to identify molecular signatures that precede dysplasia development, enabling earlier identification and management of patients at increased risk of cancer [7].

Core Insights - Microbix Biosystems Inc. is set to release its Q4 2025 financial results on December 18, 2025, prior to market opening, followed by a webinar discussion with key executives [1] Company Overview - Microbix Biosystems Inc. specializes in proprietary biological products for human health, employing over 120 skilled workers and reporting revenues of C$ 25.4 million in the last fiscal year (2024) [3] - The company supports the global diagnostics industry by providing critical ingredients and devices, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [3] - Microbix's products are utilized by approximately 100 diagnostics manufacturers, and its QAPs are available in over 30 countries through a network of international distributors [3] - The company is accredited with ISO 9001 & 13485, registered with the U.S. FDA, Australian TGA, and licensed by Health Canada, ensuring compliance with IVDR and CE marking [3] Product Development - Microbix also develops proprietary products such as Kinlytic® urokinase, a thrombolytic drug for treating blood clots, and reagents for molecular diagnostic testing [4]